NEW YORK, Dec. 17 (GenomeWeb News) -- Gyros of Uppsala, Sweden, said today that it has taken in $20 million from existing investors in a third round of financing.
The funding was led by Scandinavian Life Science Venture (SLSV) and included Investor Growth Capital, Schroder Ventures Life Sciences, 3i, Ettena Förvaltnings AB (formerly SIF), the Swedish Industrial Development Fund, InnovationsKapital, Health & Brand Capital, and Life Equity Sweden.
Gyros is commercializing a system designed to automate sample prep for MALDI mass spectrometry and boost sensitivity in protein identification. It is a new application of the company's core platform, by which laboratory processes are miniaturized and embedded into CDs for parallel preparation and processing.
Gyros was spun off from Amersham Pharmacia Biotech in 2000.